- Home
- CANF vs SFHG Comparison
CANF vs SFHG Comparison
Compare CANF & SFHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SFHG
- Stock Information
- Founded
- CANF 1994
- SFHG 1993
- Country
- CANF Israel
- SFHG Hong Kong
- Employees
- CANF N/A
- SFHG N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SFHG Publishing
- Sector
- CANF Health Care
- SFHG Consumer Discretionary
- Exchange
- CANF Nasdaq
- SFHG Nasdaq
- Market Cap
- CANF 14.8M
- SFHG 15.4M
- IPO Year
- CANF N/A
- SFHG 2024
- Fundamental
- Price
- CANF $1.04
- SFHG $0.91
- Analyst Decision
- CANF Strong Buy
- SFHG
- Analyst Count
- CANF 2
- SFHG 0
- Target Price
- CANF $14.00
- SFHG N/A
- AVG Volume (30 Days)
- CANF 172.6K
- SFHG 102.3K
- Earning Date
- CANF 05-27-2025
- SFHG 06-21-2025
- Dividend Yield
- CANF N/A
- SFHG N/A
- EPS Growth
- CANF N/A
- SFHG N/A
- EPS
- CANF N/A
- SFHG N/A
- Revenue
- CANF $674,000.00
- SFHG $19,760,935.00
- Revenue This Year
- CANF $461.72
- SFHG N/A
- Revenue Next Year
- CANF N/A
- SFHG N/A
- P/E Ratio
- CANF N/A
- SFHG N/A
- Revenue Growth
- CANF N/A
- SFHG 30.89
- 52 Week Low
- CANF $1.02
- SFHG $0.55
- 52 Week High
- CANF $4.69
- SFHG $24.00
- Technical
- Relative Strength Index (RSI)
- CANF 37.30
- SFHG N/A
- Support Level
- CANF $0.98
- SFHG N/A
- Resistance Level
- CANF $1.14
- SFHG N/A
- Average True Range (ATR)
- CANF 0.06
- SFHG 0.00
- MACD
- CANF 0.01
- SFHG 0.00
- Stochastic Oscillator
- CANF 32.59
- SFHG 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SFHG Samfine Creation Holdings Group Limited Ordinary Share
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.